48例鼻腔鼻窦肉瘤的临床分析

目的：探讨鼻腔鼻窦肉瘤的临床表现、诊断、治疗及预后，以提高对鼻腔鼻窦肉瘤的诊疗水平。方法：回顾性分析48例鼻腔鼻窦肉瘤患者的临床资料。结果：鼻腔鼻窦纤维肉瘤4例，恶性纤维性组织细胞瘤3例，脂肪肉瘤4例，平滑肌肉瘤5例，横纹肌肉瘤5例，骨肉瘤2例，软骨肉瘤3例，恶性黑色素瘤4例，非霍奇金淋巴瘤4例，浆细胞肉瘤1例，恶性神经鞘膜瘤5例，嗅神经母细胞瘤5例，血管肉瘤3例，综合治疗后随访，1，3，5年生存率分别为62．5％，46．7％，35．7％。结论：鼻腔鼻窦肉瘤不易明确诊断，结合免疫组织化学有助于诊断，对肿瘤易复发及全身转移者，综合治疗可提高生存率。     

重度妊高征并发腹水48例临床分析

目的 :分析重度妊娠高血压综合征 (简称妊高征 )并发腹水的临床特点和防治方法。方法 :将我院 1996年 1月～ 2 0 0 2年 12月间 2 0 4例重度妊高征分为并发腹水组 (A组 ,4 8例 )和未并发腹水组 (B组 ,15 6例 ) ,比较其临床特点。结果 :A、B两组间比较 ,终止妊娠的时间、肝功能检查总蛋白、白蛋白、白 /球比值、乳酸脱氢酶、血肌酐、2 4小时尿蛋白定量、宫内死胎发生率、新生儿早产发生率、孕产妇并发症的发生率差异有显著性 (P <0 .0 5 )。结论 :重度妊娠高血压综合征并发腹水病情极为严重 ,应及时终止妊娠 ,分娩后腹水可消退 ;早期、系统、定期的产前检查可及时发现、预防重度妊高征及并发症的发生。     

深圳市世界银行贷款结核病控制绩效评价

目的 对深圳市为期8年的全人口世行贷款结核病控制项目工作进行绩效评价。探讨 项目绩效评价的方法。方法 收集1993～2001年深圳市全人口结核病控制项目周期内转诊、可疑者接诊、涂阳患病、痰菌阴转、治愈情况等及费用筹集和使用的有关资料，并在项目实施前后进行结核病流行病学调查和耐药监测。从服务公平性、健康可及性、项目效果、项目效益、项目效率等方面对该项目进行评价。结果 (1)服务公平：将外来人口纳入结核病控制项目管理，实施全人口控制策略，并取得了与户籍人口一致的效果；(2)健康可及：健全了市、区、镇三级防治网络。全面实施归口管治。推行全程督导管理方式(DOTS)策略；(3)效果明显：减少了1．5万新发病人。患病率下降超过50％，初始涂阳耐多药率下降7％；(4)效益巨大：直接经济效益1．42亿元，间接经济效益挽回GDP损失30．6亿元，减少个人收入17．6亿元；(5)效率高：2月末痰菌阴转率88．8％。3月末痰菌阴转率96．0％。结论 该项目实施8年绩效明显。政府承诺保证该项目可持续发展是非常必要的。     

人原发性胆囊癌单克隆抗体制备及其特异性研究

目的 制备人原发性胆囊癌单克隆抗体,对其特异性进行研究.方法 以胆囊癌细胞系SGC-996免疫Balb/c小鼠,应用淋巴细胞杂交瘤技术,获得稳定分泌抗SGC-996单克隆抗体的阳性杂交瘤细胞.结果 杂交瘤细胞符合融合细胞核型特点,有较强的成瘤性.抗体亚类为IgG1.相对应的抗原主要表达在胞质和胞核中,分子量约为67kD抗体对胆囊癌有较强的免疫反应,其他癌组织、癌旁组织及间质、正常胆囊上皮和成纤维细胞均呈阴性.结论 建立一株杂交瘤细胞系,能稳定分泌单克隆抗体,该抗体具有较高特异性.     

器械科(处)领导如何对医用耗材实施有效管理

医用耗材的有效管理对保证医疗质量具有重要意义,也是临床工程部门器械科(处)的主要任务之一.本文通过分析医用耗材特征,提出了医用耗材管理的基本目标和原则,并结合实践给出了构建管理基础及例外管理的具体措施,为器械科(处)领导实施耗材的有效管理提供参考.     

9岁女患儿的原发性气管雪旺细胞瘤（神经鞘瘤）

作者报道1例患原发性气管雪旺细胞瘤(神经鞘瘤)的9岁女患儿合并气道梗阻。CT扫描发现气管内多息肉样肿块,73%的管腔发生梗阻。行气管部分切除及吻合术。病检确诊为起源于雪旺细胞的良性神经源性肿瘤。9岁女患儿的原发性气管雪旺细胞瘤(神经鞘瘤)@Nio M. @Sano N. @Kotera     

1995～2004年广东省医院管理研究文献量的统计分析

引用中国生物医学光盘数据库(CBMdisc)收录全国及广东省十年间医院管理发表的文献量、全国10大城市医院管理的文献量排名和广东省内21个省市级医院发表医院管理文献量排名等进行统计分析,并且提出建议。     

Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review.

We reviewed all English-language articles on associations among circulating levels of the insulin-like growth factors (IGF) and their binding proteins (IGFBP), polymorphisms in their genes, and breast cancer risk. In premenopausal women, five of eight IGF-I studies and four of six IGFBP-3 studies of circulating levels found that women in the highest quantile had more than twice the risk of developing breast cancer of those in the lowest, although in some this effect was only apparent at young ages. In postmenopausal women, however, there was no consistent effect. A simple sequence length polymorphism 1 kb 5' to IGF-I was examined in relation to circulating levels of IGF-I (12 studies) or breast cancer risk (4 studies), but there was no convincing evidence of any effect. For an A/C polymorphism 5' to IGFBP-3, all three studies were consistent with a modest effect on circulating levels, but no evidence of a direct effect on breast cancer risk was seen in the only relevant study. Variation within the reference range of IGF-I and IGFBP-3 may confer only modest increases in breast cancer risk, and any single polymorphism may only account for a small proportion of that variation. Nevertheless, population attributable fractions for high circulating levels of IGF-I and IGFBP-3 and for common genetic variants could be substantial. Further large studies, or combined analysis of data from existing studies, are needed to quantify these effects more precisely.     

Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer.

PURPOSE: Tumor necrosis treatment (TNT) uses degenerating tumor cells and necrotic regions of tumors as targets for radioimmunotherapy. Previous studies in animal tumor models and clinical trials have demonstrated that when linked to the therapeutic radionuclide iodine-131, recombinant chimeric TNT antibody ((131)I-chTNT) can deliver therapeutic doses to tumors regardless of the location or type of malignancy. Therapeutic efficacy and toxicity of (131)I-chTNT in advanced lung cancer patients were studied in this pivotal registration trial. PATIENTS AND METHODS: Patients with advanced lung cancer were treated with systemic or intratumoral injection of (131)I-chTNT in eight oncology centers in China. The objective response rate (ORR) was assessed as the primary end point. RESULTS: All 107 patients who were entered onto the study and completed therapy had experienced treatment failure after prior radiotherapy or chemotherapy a mean of three times. The results showed an ORR of 34.6% (complete response, 3.7%; partial response, 30.8%; no change, 55.1%; and progressive disease, 10.3%) in all patients and 33% in 97 non-small-cell lung cancer patients. A biodistribution study demonstrated excellent localization of the radioactivity in tumors in both systemically and intratumorally injected patients. The most obvious adverse side effect was mild and reversible bone marrow suppression. CONCLUSION: Radioimmunotherapy with (131)I-chTNT was well tolerated and can be used systemically or locally to treat refractory tumors of the lung.